Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
Introduction: Colorectal cancer is one of the most prevalent tumors in the world. In the surveillance setting of recurrent colorectal cancer, laboratory test like carncinoembryonic antigen (CEA) and imaging tests like computed tomography (CT) and positron emission tomography (PET/CT) are available. We performed this study to establish the predictive accuracy of these tests to an early identification of recurrent colorectal cancer. Materials and Methods: Thirty six patients at stages I, III and IV, after single metastasis resection of colorectal cancer were identified. We assessed the utility of CEA, CT and PET-CT in the follow-up of these patients to improve the diagnosis of recurrent disease. Results: Of 36 studied patients, 27 (75%) had recurrence; the median age was 61 year-old and the median lap-time 16 months. The PET/CT scan obtained the following results: sensitivity 96.7%, specificity 88.9%, positive predictive value 96.3%, negative predictive value 88.9%, posititve likelihood ratio 8.7and negative likelihood ratio 0.04. Discusion: The best tool to make diagnosis of colorectal cancer and its recurrence is PET–CT, however, none of these tests could make the diagnosis by themselves. It has to be confirmed by histopathologic studies plus other exams.
American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016.
SEER Cancer Statistics Factsheets: Colon and Rectum Cancer. National Cancer Institute. Bethesda, MD,http://seer.cancer.gov/statfacts/html/colorect.html
Cueva P, Yépez J. Epidemiología del cáncer en Quito 2006-2010. Quito: SOLCA; 2014 [consultado 20 de enero, 2016], Disponible en: http://issuu.com/solcaquito/docs/epidemiologia_de_cancer_en_quito_20/1.
Henríquez H, Centro Gastrointestinal de Guatemala.
Enfermedades del colon, recto y ano. Coloproctología enfoque clínico y quirúrgico. 1a: AMOLCA: 2013. pag 1573-1595.
Duffy MJ. Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is it Clinically Useful?. Clin Chem. 2001; Apr;47(4):624-30.
Workman R, Coleman R. Pet CT. Essentials for clinical practice North Carolina: Springer; 2006.
Zhang C, Chen Y, Xue H, Zheng P, Tong J, Lui J, et al.
Diagnostic value of FDG-PET in recurrent colorectal carcinoma: A meta-analysis. Int J Cancer 2009 Jan 1;124(1):167-73.
Nakamoto Y, Sakamoto S, Okada T, Senda M, Higashi T, Saga T, et al. Clinical Value of Manual Fusion of PET and CT Images in Patients with Suspected Recurrent Colorectal Cancer. AJR Am J Roentgenol. 2007 Jan;188(1):257-67.
Kim JH, Czernin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, et al. Comparison Between 18F-FDG PET, In-Line PET/CT, and Software Fusion for Restaging of Recurrent Colorectal Cancer. J Nucl Med. 2005 Apr;46(4):587-95.
Ponce J, Castells A, Gomollpon F, et al. Tratamiento de las enfermedades gastroenterológicas. 3rd ed.: Asociacion Española de Gastroenterología; 2011: 359-372.
Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20898 patients on 18 randomized trials. J Clin Oncol. 2005 Dec 1;23(34):8664-70. Epub 2005 Oct 31.
Tapia OE, Roa JC, Manterola C, Bellolio E. Colon and Rectum Cancer: Morphological and Clinical Description of 322 Cases. Int. J. Morphol. 2010; 28(2):393-398.
Siegel R, Desantis C, Jemal A. Colorectal Cancer Statistics, 2014. CA Cancer J Clin. 2014 Mar- Apr;64(2):104-17
Martí-Ragué J, Parés M, Biondoa S, Navarro M, Figueras J, de Oca J, et al. Supervivencia y recidiva en el tratamiento multidisciplinario del carcinoma colorrectal. Medicina Clínica. 2004; 123(08): 291-296.
Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003 Oct 6;3:26.
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.